Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes

被引:52
作者
Golino, P [1 ]
Ravera, A [1 ]
Ragni, M [1 ]
Cirillo, P [1 ]
Piro, O [1 ]
Chiariello, M [1 ]
机构
[1] Univ Naples Federico II, Div Cardiol, Dept Internal Med & Cardiovasc Sci, Naples, Italy
关键词
inhibitors; tissue factor pathway; tissue factor; acute coronary syndromes;
D O I
10.1161/01.CIR.0000105900.21445.3D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Tissue factor pathway inhibitor (TFPI) is the endogenous inhibitor of the extrinsic coagulation pathway; however, its involvement during thrombus formation in patients with acute coronary syndromes (ACS) is still unknown. Methods and Results-Transcardiac (aorta/coronary sinus) free and total TFPI (free + lipoprotein-bound form) levels, as well as TFPI/factor Xa (FXa) complex levels, were measured in plasma samples obtained from patients with acute myocardial infarction undergoing primary PTCA and patients with unstable angina undergoing urgent PTCA. Patients with stable angina undergoing elective PTCA served as controls. In addition, prothrombin fragment 1 + 2 and fibrinopeptide A plasma levels were measured. Samples were collected at baseline, after PTCA, and after stent deployment. In patients with ACS, both total and free TFPI plasma levels in the coronary sinus were significantly lower than the corresponding levels measured in the aorta at any time point of the study; conversely, a significant increase in TFPI/FXa complex plasma levels was observed in the coronary sinus as compared with the aorta. In contrast, in patients with stable angina, no differences were observed in TFPI and TFPI/FXa levels at baseline in the coronary sinus as compared with the aorta. Conclusions-TFPI is involved in the process of thrombus formation in vivo in patients with ACS, which suggests a potential role for TFPI in modulating coronary thrombosis.
引用
收藏
页码:2864 / 2869
页数:6
相关论文
共 36 条
[1]   DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES [J].
ANNEX, BH ;
DENNING, SM ;
CHANNON, KM ;
SKETCH, MH ;
STACK, RS ;
MORRISSEY, JH ;
PETERS, KG .
CIRCULATION, 1995, 91 (03) :619-622
[2]   Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].
Badimon, JJ ;
Lettino, M ;
Toschi, V ;
Fuster, V ;
Berrozpe, M ;
Chesebro, JH ;
Badimon, L .
CIRCULATION, 1999, 99 (14) :1780-1787
[3]  
BROZE GJ, 1992, SEMIN HEMATOL, V29, P159
[4]  
BROZE GJ, 1988, BLOOD, V71, P335
[5]  
BROZE GJ, 1995, BLOOD COAGUL FIBRIN, V6, P7
[6]   Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels [J].
Crawley, J ;
Lupu, F ;
Westmuckett, AD ;
Severs, NJ ;
Kakkar, VV ;
Lupu, C .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (05) :1362-1373
[7]  
DAVIES SW, 1993, BRIT HEART J, V69, P3
[8]  
Drew AF, 1997, LAB INVEST, V77, P291
[9]   MEASUREMENT OF CORONARY SINUS BLOOD FLOW BY CONTINUOUS THERMODILUTION IN MAN [J].
GANZ, W ;
TAMURA, K ;
MARCUS, HS ;
DONOSO, R ;
YOSHIDA, S ;
SWAN, HJC .
CIRCULATION, 1971, 44 (02) :181-&
[10]   Blood-borne tissue factor:: Another view of thrombosis [J].
Giesen, PLA ;
Rauch, U ;
Bohrmann, B ;
Kling, D ;
Roqué, M ;
Fallon, JT ;
Badimon, JJ ;
Himber, J ;
Riederer, MA ;
Nemerson, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2311-2315